Literature DB >> 22179068

Chemical informatics and target identification in a zebrafish phenotypic screen.

Christian Laggner1, David Kokel, Vincent Setola, Alexandra Tolia, Henry Lin, John J Irwin, Michael J Keiser, Chung Yan J Cheung, Daniel L Minor, Bryan L Roth, Randall T Peterson, Brian K Shoichet.   

Abstract

Target identification is a core challenge in chemical genetics. Here we use chemical similarity to computationally predict the targets of 586 compounds that were active in a zebrafish behavioral assay. Among 20 predictions tested, 11 compounds had activities ranging from 1 nM to 10,000 nM on the predicted targets. The roles of two of these targets were tested in the original zebrafish phenotype. Prediction of targets from chemotype is rapid and may be generally applicable.

Entities:  

Mesh:

Year:  2011        PMID: 22179068      PMCID: PMC3262069          DOI: 10.1038/nchembio.732

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


Chemical genetics seeks to identify the targets responsible for phenotypes responding to organic small molecules, just as genetic screens identify the molecular players involved in cellular processes. Since the chemical perturbation is non-genetic, this must be done biochemically,[1] proteomically,[2,3] or by phenotypic pattern recognition.[4,5] Such approaches can be laborious and many low-abundance proteins are outside of their purview. Several investigators thus have turned to inference-based methods that combine experiment and computation. Multidimensional screening of hundreds of cell lines by tens of thousands of molecules has led to patterns that can illuminate target identity,[6,7] as can matching the transcriptional patterns provoked by an organic molecule to those provoked by molecules with known mechanisms.[8,9] Less explored are purely computational methods for target identification, especially those motivated by ligand structure, the basis of target identification in classical pharmacology.[10] With the advent of large ligand-protein databases, hundreds of thousands of ligands annotated to thousands of molecular targets are available. This has enabled a redrawing of receptor relationships based on both shared ligands,[11] and ligand-disease associations,[12] which in turn has been exploited to predict previously unknown targets for drugs.[13,14] By the same logic, such an approach might be used to predict the targets of organic molecules active in phenotypic screens. We thus sought to identify the targets of 681 neuroactive molecules from a 14,000 compound phenotypic screen in zebrafish embryos, measuring the modulation of characteristic movement responses to a series of light flashes (a photomotor response, PMR).[15] For each compound, patterns were observed for eight to ten embryos, and 14 behavioral features of the PMR were compared to untreated animals (Supplementary Results, Supplementary Fig. 1 and Supplementary Methods).[15] Of the 681 actives, 162 were drugs, chemical probes or naturally occurring molecules, 61 of which had one or more targets annotated in ChEMBL, leaving a total of 620 compounds unannotated. We computationally screened these against the ChEMBL database (https://www.ebi.ac.uk/chembldb/) using the Similarity Ensemble Approach (SEA).[13,16] In the filtered version we used, ChEMBL annotates over 167,000 organic molecules for activities against over 2,000 molecular targets. SEA scores shared patterns of chemical functionality between the “bait” molecules and all of the ligands annotated to a target (the ligand-target set), using one of several topological, bit-string fingerprints.[17,18] Similarity values are measured by Tanimoto coefficients (TC),[19] which range from 0 (no bits in common) to 1 (all bits shared). The similarities between a bait molecule and a ligand-target set were summed and compared to those expected at random. Using the statistical machinery developed for BLAST sequence comparisons, this led to expectation values (E-values) for the similarity versus a random background.[13,16,20] In a variation introduced here, bait molecules that bore formal charges that were atypical for a ligand-target set were excluded (Supplementary Fig. 2). The method is limited to those targets with known ligands. Still, most target categories are covered, all of which are “ligandable”. For instance, using the widely-used ECFP4 fingerprint,[17] 473 of the 681 molecules were predicted to be active on 945 targets with E-values better than 10−5 (Fig. 1); at a more stringent E-value of 10−20, 284 molecules were predicted to be active on 404 targets. Similar results were obtained for the other fingerprints, resulting in combined predictions for 586 compounds with E-values < 10−5. Targets with strong predictions included G Protein-Coupled Receptors (GPCRs), ligand-gated ion channels, nuclear hormone receptors, transporters, and soluble enzymes (Supplementary Table 1).
Figure 1

The number of compounds for which at least one target is predicted as a function of expectation value vs. random (E-value)

Higher E-values are less stringent. Only E-values below (better than) 10−5 were considered in this analysis.

We emphasized targets that were predicted with strong E-values, that were previously unknown for the phenotypically active molecules, and that were experimentally accessible to us. For this study, we investigated GPCRs, ion channels, transporters, and kinases. Many target predictions were unknown in ChEMBL but were subsequently were found on literature search (Supplementary Table 2). Since we were interested in novel predictions, we focused on 20 compounds predicted against unknown targets. Of these, 11 were active at 22 of the 31 targets against which they were predicted (Table 1, Supplementary Fig. 3); 9 compounds had no measurable activity on their predicted targets and these associations are considered falsified (Supplementary Table 3). Potencies, measured in full concentration-response, ranged from about 10 µM to low nanomolar (Table 1, Supplementary Fig. 3). As noted previously[14] there was little correlation between potency and SEA E-value. Potency is ignored in weighting the ligand similarities in SEA; E-values only indicate the likelihood that the compound will be active at a relevant concentration.[13,16]
Table 1

Target predictions, E-values (ECFP4), maximum Tanimoto coefficient and binding affinities for compounds active in the Zebrafish photomotor response screen.

Cpd.PMR PlotaPredictedtargetsE-valueMax. TCKi (nM)
β1 AR2.99×10−180.47337
β2 AR4.69×10−150.43728
β3 AR4.55×10−190.47589

β1 AR--965
β2 AR2.98×10−05b0.61b550
β3 AR2.98×10−05b0.61b3128

dopamine D23.54×10−330.63120
dopamine D38.16×10−410.63> 10,000
dopamine D41.00×10−240.495.0
α1A AR2.07×10−480.49113.6
α1B AR1.19×10−480.4929.7
α1D AR3.89×10−480.4925.4
α2A AR2.01×10−270.43164
α2B AR2.83×10−260.4396.4
α2C AR1.84×10−260.4380.8
5-HT1A3.83×10−670.5365.0
5-HT1B1.62×10−160.499422
5-HT1D7.55×10−170.49153

dopamine D22.78×10−420.554869
dopamine D31.46×10−460.58946
dopamine D42.25×10−490.581181
5-HT1A1.24×10−310.532439
5-HT1B1.61×10−120.53> 10,000
5-HT1D2.32×10−160.534512

dopamine D22.15×10−380.66207
dopamine D39.25×10−440.65164
dopamine D48.28×10−250.47530

Kv1.14.05×10−710.72n.d.
Kv1.29.40×10−850.721930c
Kv1.31.28×10−140.72n.d.

Kv1.19.69×10−560.56n.d.
Kv1.21.18×10−660.562810c
Kv1.31.74×10−100.56n.d.

oxytocin1.60×10−260.52> 10,000
vasopressin8.32×10−100.52690
1A

SERT2.06×10−190.526200d

ABL21.62×10−540.427460c,e
SRC3.38×10−340.423820c,e
LCK2.51×10−300.451890c,e

p38α2.68×10−100.4247% Inh.@ 1µM

The aggregate motor activity of 10 zebrafish embryos during the PMR assay. The y-axis and x-axis represent the motion index and time, respectively. Red vertical bars at 10s and 23s represent the timing and duration of the stimulus.

Calculated with Daylight fingerprints (note that TC values are not comparable across different fingerprints; Daylight fingerprints usually give higher TC values than ECFP4 for the same compound pairs).

IC50 (nM).

EC50 (nM).

Assuming competitive inhibition, and based on the Cheng-Prusoff equation, Ki values would be about half the IC50 values for the kinase inhibitors.

It is appropriate to consider the accuracy and the novelty of the predictions. Arguably, any method that used a library of ligand-target sets, such as ChEMBL, and a metric of chemical similarity could have predicted targets for some of these molecules. For instance, pair-wise compound similarity alone, or one of the more sophisticated methods now available,[7,11,12,21,22] may well have suggested that compounds 6 and 7 targeted the Kv1.2 potassium channel, or that 8 targeted vasopressin receptors. Any such approach must confront the problem of what level of chemical similarity usefully identifies likely targets; if one’s similarity cut-off is too permissive it will capture too many targets, and if too stringent many likely targets will be missed. For instance, the pair-wise similarity of 2 for βAR ligands and of 3 for α2AR ligands never rose above a Tanimoto coefficient (TC) of 0.61 (Daylight fingerprints) or 0.43 (ECFP4 fingerprints), respectively. At these relatively low similarities, a simple 2D similarity search of ChEMBL predicts 217 targets for 2 and 57 targets for 3, many of which will be false positives. SEA attempts to address this problem by comparing similarities to those expected at random, and by comparing any bait molecule to an entire ligand-target set.[13,16] This at once increases the number of targets addressable, ranks the predictions by confidence level, and eliminates many predictions that hang by a bait’s association with one or two ligands in a target set that might annotate hundreds of molecules. Because SEA is model-free and uses all information represented in a fingerprint, without weighting, it can interrogate any ligand-target set for similarity to any bait molecule without defining warheads or pharmacophores. A key challenge, for us and for the field, is linking the targets for which in vitro affinity is measured to the in vivo phenotype that was originally observed. One way to investigate this, is to test another molecule, known to be active on the target but structurally dissimilar to the active compound from the phenotypic screen, for its ability to phenocopy the original “bait” molecule in the animal or cell.[23] The voltage-gated potassium channel Kv1.2 is attractive for this purpose in that it is modulated by structurally diverse molecules. Psora-4 (12), for instance, has low- to mid-nanomolar activity at members of the Kv1 family, including Kv1.2, but is structurally orthogonal to compounds 6 and 7. Consistent with the prediction that compounds 6 and 7 exert their excitatory phenotype by blocking this family of ion channels, the photomotor response (PMR) induced by the chemically unrelated compound 12 closely resembled that of compounds 6 and 7 (Fig. 2, Supplementary Fig. 4).
Figure 2

Testing target relevance by phenocopy and functional competition. Compounds 6 and 7 phenocopy the known Kv inhibitor psora-4 (12)

The PMR phenotypes of animals treated with (a) DMSO, (b) compound 12, (c) compound 6. The same phenotype was obtained for compound 7 (see Table 1). (d) Bar plot showing the mean number of motor activity spikes in animals treated with DMSO, compound 12, compound 7, and compound 6. Activities during background, excitation and refractory phases of the PMR are shown. Compound 1 suppresses β-AR agonist-induced motor excitation. The PMR phenotypes of animals treated with: (e) compound 13 (isoproterenol), (f) compound 13 and the known β-AR antagonist compound 14 (bopindolol) together (g) compounds 13 and 1. (h) Bar plot showing the mean number of motor activity spikes in animals treated with DMSO, compound 13, compounds 13 and 14, and compounds 13 and 1. Activities during background, excitation and refractory phases of the PMR are shown. Bars in panels d and h represent mean values ± s.d.

A second pharmacological test for a target-based effect is to use the screening compound to compete against the function of a known ligand for the target of interest. We tested the ability of compound 1 to reverse the activity of the β-adrenergic agonist isoproterenol (13), an excitatory ligand in the PMR assay. Consistent with the prediction and in vitro observation of activity on the β-adrenergic receptors, compound 1 reversed the isoproterenol’s excitatory PMR, doing so as well as the well-known β-adrenergic antagonist bopindolol (Fig. 2, Supplementary Fig. 5). Meanwhile, 1 did not reverse the excitatory phenotype of drugs acting on other receptor classes, such as the digitoxigenins, nor did sedative drugs from other classes reverse the excitatory activity of isoproterenol (Supplementary Fig. 6). These results are consistent with the zebrafish phenotype of compound 1 being mediated via β-adrenergic receptors. A chemoinformatic approach to target identification in phenotypic screens has important advantages and may complement empirical approaches: it is rapid, has a relatively high success rate, and can address both high- and low-abundance targets. Admittedly, there are important cautions: the approach is limited to liganded targets, and even for these almost a half of the predictions that were tested were falsified, as was true in earlier studies.[13,14] Still, this success rate seems high enough to be useful for target prioritization for testing. Especially when a purely empirical screen is laborious, and when low-abundance targets will be missed, this and related methods[11,12,22,24] will usefully complement purely experimental approaches. Although establishing that a molecule is active against a particular target does not establish the role of that target in the phenotype, it does provide a testable molecular hypothesis. Whereas the method is restricted to the targets for which ligand information is available, one can at least be sure that these are “ligandable”, and that small molecule probes already exist within that small part of chemical space that has been explored.[25] Within this set, the method is systematic and comprehensive enough to suggest testable targets for most of the ligands active in even a diverse ligand library, such as tested here (Table 1). It may thus find broad application to target identification in phenotypic screens; to this end we have developed a public website from which the method may be accessed by the community (http://sea.bkslab.org/ and http://sea.bkslab.org/search/).
  22 in total

1.  Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis.

Authors:  S J Haggarty; T U Mayer; D T Miyamoto; R Fathi; R W King; T J Mitchison; S L Schreiber
Journal:  Chem Biol       Date:  2000-04

2.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

3.  Global mapping of pharmacological space.

Authors:  Gaia V Paolini; Richard H B Shapland; Willem P van Hoorn; Jonathan S Mason; Andrew L Hopkins
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

4.  Identifying the proteins to which small-molecule probes and drugs bind in cells.

Authors:  Shao-En Ong; Monica Schenone; Adam A Margolin; Xiaoyu Li; Kathy Do; Mary K Doud; D R Mani; Letian Kuai; Xiang Wang; John L Wood; Nicola J Tolliday; Angela N Koehler; Lisa A Marcaurelle; Todd R Golub; Robert J Gould; Stuart L Schreiber; Steven A Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

5.  Drug-target network.

Authors:  Muhammed A Yildirim; Kwang-Il Goh; Michael E Cusick; Albert-László Barabási; Marc Vidal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

Review 6.  Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential.

Authors:  Rahul Palchaudhuri; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2010-12-23       Impact factor: 5.100

7.  Quantifying biogenic bias in screening libraries.

Authors:  Jérôme Hert; John J Irwin; Christian Laggner; Michael J Keiser; Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2009-05-31       Impact factor: 15.040

8.  Rapid behavior-based identification of neuroactive small molecules in the zebrafish.

Authors:  David Kokel; Jennifer Bryan; Christian Laggner; Rick White; Chung Yan J Cheung; Rita Mateus; David Healey; Sonia Kim; Andreas A Werdich; Stephen J Haggarty; Calum A Macrae; Brian Shoichet; Randall T Peterson
Journal:  Nat Chem Biol       Date:  2010-01-17       Impact factor: 15.040

9.  Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.

Authors:  Sarah L Kinnings; Nina Liu; Nancy Buchmeier; Peter J Tonge; Lei Xie; Philip E Bourne
Journal:  PLoS Comput Biol       Date:  2009-07-03       Impact factor: 4.475

10.  ChemBank: a small-molecule screening and cheminformatics resource database.

Authors:  Kathleen Petri Seiler; Gregory A George; Mary Pat Happ; Nicole E Bodycombe; Hyman A Carrinski; Stephanie Norton; Steve Brudz; John P Sullivan; Jeremy Muhlich; Martin Serrano; Paul Ferraiolo; Nicola J Tolliday; Stuart L Schreiber; Paul A Clemons
Journal:  Nucleic Acids Res       Date:  2007-10-18       Impact factor: 16.971

View more
  51 in total

1.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Validation strategies for target prediction methods.

Authors:  Neann Mathai; Ya Chen; Johannes Kirchmair
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

3.  Computational studies to predict or explain G protein coupled receptor polypharmacology.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Silvia Paoletta
Journal:  Trends Pharmacol Sci       Date:  2014-11-14       Impact factor: 14.819

Review 4.  Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.

Authors:  Bryan L Roth; Wesley K Kroeze
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

5.  A Simple Representation of Three-Dimensional Molecular Structure.

Authors:  Seth D Axen; Xi-Ping Huang; Elena L Cáceres; Leo Gendelev; Bryan L Roth; Michael J Keiser
Journal:  J Med Chem       Date:  2017-08-08       Impact factor: 7.446

Review 6.  Shifting from the single to the multitarget paradigm in drug discovery.

Authors:  José L Medina-Franco; Marc A Giulianotti; Gregory S Welmaker; Richard A Houghten
Journal:  Drug Discov Today       Date:  2013-01-20       Impact factor: 7.851

7.  An Aggregation Advisor for Ligand Discovery.

Authors:  John J Irwin; Da Duan; Hayarpi Torosyan; Allison K Doak; Kristin T Ziebart; Teague Sterling; Gurgen Tumanian; Brian K Shoichet
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

8.  A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination.

Authors:  Lauren R Strachan; Tamara J Stevenson; Briana Freshner; Matthew D Keefe; D Miranda Bowles; Joshua L Bonkowsky
Journal:  Hum Mol Genet       Date:  2017-09-15       Impact factor: 6.150

9.  An in vivo platform for rapid high-throughput antitubercular drug discovery.

Authors:  Kevin Takaki; Christine L Cosma; Mark A Troll; Lalita Ramakrishnan
Journal:  Cell Rep       Date:  2012-07-20       Impact factor: 9.423

Review 10.  Advances in zebrafish chemical screening technologies.

Authors:  Jonathan R Mathias; Meera T Saxena; Jeff S Mumm
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.